Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. DAYBUE net sales were $125 million (+30%) and NUPLAZID net sales $183 million (+10%). 2026 sales guidance: DAYBUE $480-$510M, NUPLAZID $760-$790M, total revenue $1.24-$1.30B. Net income was $32M ($0.18/share).
How this was made
The 30-second read
Why it matters
The most decision-relevant items are the raised DAYBUE sales guidance and the updated total 2026 revenue range, alongside changes to R&D and SG&A guidance and specific adoption metrics (powder formulation share, referral mix, provider reach).
Market read
Traders can update 2026 revenue expectations for ACAD based on raised DAYBUE guidance and the revised total revenue range, while monitoring later 2026 clinical and European launch milestones.
What to watch
Gross-to-net adjustment ranges were updated (DAYBUE full-year 23% to 25%), so investors should watch whether pricing/reimbursement dynamics worsen even if top-line guidance rises.
Background
This is a transcript-style summary of Acadia Pharmaceuticals’ Q2 2026 earnings call, covering commercial performance for DAYBUE and NUPLAZID and updates to 2026 guidance and pipeline timelines.
Ticker impact
Acadia raised 2026 DAYBUE sales guidance to $480 million to $510 million and updated total 2026 revenue guidance to $1.24 billion to $1.30 billion.
Bias toward upside for ACAD on guidance-follow-through, with volatility risk around later clinical readouts (RADIANT top-line expected Sep-Oct 2026) and European launch execution.
The article provides specific, time-bound financial guidance changes (DAYBUE and total revenue) plus concrete commercial adoption metrics, which typically drive near-term repricing. However, the transcript also flags pipeline milestones later in 2026, which can dominate sentiment if outcomes disappoint.
Market effects
Reinforces demand and formulation-adoption momentum in CNS specialty pharma, potentially supporting sentiment for peers with similar commercial execution risk.
Highlights planned early Q4 2026 Germany launch for trofinetide, which may influence regional expectations for neurology drug commercialization in Europe.
Pipeline timelines (Japan Phase III readout Sep-Nov 2026, regulatory submission in 2027) keep global development calendars in focus for investors tracking CNS assets.
Counterpoint
Raised guidance could be partially offset by margin pressure from higher SG&A (field force expansion) and by uncertainty around upcoming clinical readouts that may not translate into near-term revenue.
Key entities
- companyAcadia Pharmaceuticals
Subject of the earnings call transcript; management updated 2026 guidance and provided pipeline and commercial adoption milestones.
- productDAYBUE
Rett syndrome treatment; guidance raised and adoption metrics cited for the new powder formulation.
- productNUPLAZID
Alzheimer’s disease psychosis and Lewy body dementia psychosis treatment; guidance reaffirmed with volume growth noted.
- pipeline_programremlifanserin
Management cited estimated peak sales potential of $4 billion and discussed Phase II RADIANT enrollment and expected top-line results.
- pipeline_programtrofinetide
Management indicated plans for Germany launch in early Q4 2026 and a Japan Phase III readout window of Sep-Nov 2026.
